Clinical Pathways Congress + Cancer Care Business Exchange’s Post

Prioritising breast cancer research should start with considering the most important voices: the patients. LYDIE MEHEUS, managing director at the Anticancer Fund, and a patient advocate in BIG's Patient Partnership Initiative, joined the #BIGNCTN Annual Meeting, which recently convened experts from around the world, to represent patients participating in clinical trials. Incorporating patients' perspectives into the #BIGNCTN annual meeting is vital for identifying the pressing issues in breast cancer treatment and care. It also helps researchers to focus on areas that may not receive enough attention from the pharmaceutical industry and to establish large international research programmes that prioritise patients' needs. #BIGagainstBC #BreastCancer #BreastCancerResearch #EU4Health European Health and Digital Executive Agency (HaDEA)

We are thrilled to announce the release of our latest Oncology Report, highlighting the transformative progress being made in the fight against advanced #cancers. Here's a glimpse of what’s inside: #PrecisionMedicine: Focused on underserved patient subpopulations #InnovativeTherapies: Antibody-drug conjugates and radioligand therapies are taking center stage in clinical trials. Improved Success Rates: #Oncology clinical development success rates reached 12% in 2024, up from 10% in 2023, driven by streamlined trials and enhanced productivity. #AIinResearch: Artificial intelligence is shaping the future of oncology, boosting efficiency and driving breakthroughs. Comprehensive Insights: From top medications and spending trends to #regulatory updates and M&As, this report offers a global perspective. The relentless pursuit of better outcomes for cancer patients continues to be fueled by scientific innovation and collaborative efforts. Discover the details: https://lnkd.in/eDykJNMq Together, let’s accelerate progress in oncology and improve lives around the world. #Oncology #PrecisionMedicine #Innovation #Healthcare

Based on a survey of 100 Canadian #oncologists and other #cancer treaters, 89% of physicians believe that the resources and information provided by MSLs have a positive impact on the care they provide for their patients. Many oncologists look to MSLs to keep them up to date on new developments and #clinical data for their products and in cancer types, as well as providing insights into research and development at their companies and opportunities to participate in clinical trials. This reveals the role of the MSL as an integral part of an oncology company’s relationship with the medical community. Knowing how your teams perform – and how they compare against your competitors – can impact future success. The 2024 Oncology Industry Insights (formerly OncoMETRIKS) MSL Performance Report provides valuable, current insights on this important piece of your HCP engagement strategy. Contact IQVIA today to learn more about this and other reports on HCPs’ perceptions of the oncology landscape. #medicalscienceliaison #cdnpharma #oncology #pharma Arushi Sharma Nikhil Nath Francois Lussier Mazen Baradhy

Sharing clinical trial data openly is essential for better treatments and patient care. https://lnkd.in/e7HR28NN In this blog, you will learn about the significance of clinical trial transparency in cancer research, its evolution, and persistent gaps. Explore the impact of regulatory frameworks like the EU Clinical Trials Regulation and efforts by organizations like the Anticancer Fund in promoting transparency. Discover the latest developments in improving reporting standards and the Anticancer Fund's commitment to advancing clinical trial transparency. Written by Kristine Beckers. #anticancerfund #cancerresearch #clinicaltrials #antikankerfonds European Medicines Agency European Cancer Organisation EORTC - European Organisation for Research and Treatment of Cancer ESMO - European Society for Medical Oncology

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments: Expert discussed benefits of precision oncology treatments that utilize thousands of biomarkers to design personalized treatment plans. #finance #pharmacy #lifesciences

Yet another tremendous milestone for Enhertu as this marks its "fifth" FDA approved indication, giving more patients another cancer treatment option. Other noteworthy achievements: 1) "1st" ADC to gain tissue-agnostic (HER2) approval from the FDA 2) "7th" medicine to achieve this type of approval, following pembrolizumab (MSI-H/dMMR and TMB-H), larotrectinib (NTRK), entrectinib (NTRK), dostarlimab (dMMR), dabrafenib + trametinib (BRAF V600E), and selpercatinib (RET)

At Lampgen Clinical Research, we are committed to supporting groundbreaking advancements in oncology through expert staffing solutions for sponsors and CROs. The recent “remarkable” results of CAR T-cell therapies in treating multiple myeloma highlight the potential of innovative treatments to transform patient outcomes. FDA-approved therapies like idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel; Carvykti) have shown significant efficacy, marking a new era in multiple myeloma treatment. With impressive overall response rates and expanded indications, these therapies offer hope to patients who have exhausted other options. Our experienced oncology CRAs ensure that clinical trials are conducted with the highest standards of ICH/GCP compliance. As a trusted partner in clinical research, Lampgen is proud to contribute to these vital studies, helping to bring life-changing therapies to patients faster. #OncologyResearch #ClinicalTrials #CAR_TCellTherapy #MultipleMyeloma #FDAApproval #CancerTreatment #ClinicalResearch #PharmaStaffing #ICHGCP #LampgenClinicalResearch #DrugDevelopment #ClinicalResearchStaffing #OncologyCRAs 🔗 https://lnkd.in/eFhD8Pwm

Did you know that the recent findings of DESTINY-Breast06 phase III study, supported by AstraZeneca in collaboration with Daiichi Sankyo Brasil , demonstrated that trastuzumab deruxtecan significantly improved progression-free survival (PFS) compared to chemotherapy in patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after prior endocrine therapy? The trial highlighted consistent benefits across both HER2-low and HER2-ultralow groups, suggesting no need for further differentiation between these categories. While safety remained aligned with expectations, interstitial lung disease continues to pose a risk. The findings, presented at the ESMO Congress 2024, also confirmed trastuzumab deruxtecan’s role in preserving quality of life compared to chemotherapy. #health #healthresearch #healthsolutions #scientificcommunication #scientificresearch #researchanddevelopment #oncology

Cancer is a pandemic, and the need for innovative clinical trials has never been greater. Global spending on cancer treatments is projected to reach $409 billion by 2028, nearly double the $223 billion spent in 2023, according to the IQVIA Global Oncology Trends 2024 report. This sharp rise highlights the growing burden of cancer and the need for more efficient, accessible trials. Decentralized clinical trials (DCTs) are revolutionizing the way research is conducted, allowing patients to participate remotely and expediting the development of life-saving therapies. The recent updates to the ICH E6 guidelines (Annex 2) are a significant step forward in addressing these challenges. By focusing on integrating advanced technology and ensuring robust regulatory compliance, these updates will help ensure that clinical trials can adapt to the fast-evolving landscape of oncology research. Kudos to the authorities for such a timely and relevant update, which will undoubtedly streamline trial management and improve patient access to cutting-edge therapies. #CRO #OncologyTrials #ClinicalTrials #DecentralizedTrials #Innovation #MyrtleCRO #CancerResearch

Oncology investment is set to exceed $375 billion by 2037, driving groundbreaking treatments and innovations. Despite these advancements, however, many people cannot access care due to geography, race, ethnicity, culture, and more. At this year's American Society of Clinical Oncology (ASCO) conference, BCGers joined with other healthcare experts to discuss the issue and potential solutions. Moving forward, stakeholders across the healthcare ecosystem can collaborate to ensure that emerging cancer therapies are equitable and accessible to all. The latest BCG article, "Ensuring Access and Equity for Breakthrough Therapies in Oncology," by Priya Chandran, Dr Jon Cleland, MD, Gian King, PharmD, Troy Mullane, and Cat Reville, explores how governments and biopharma leaders can broaden access to emerging oncology treatments: https://lnkd.in/g6iQRg54 #BCGatASCO2024